DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Shima M, Nagao A, Taki M. et al.
Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: a phase 1/2 study in patients with severe haemophilia A.
Haemophilia 2021;
27 (01) 81-89
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.